Health and Healthcare

Biotech Busine$$ Daily (AMLN, BIIB, CEPH, CYTK, ONXX, REGN, THRX, CBM)

Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers:

  • Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to $28.97, a 5% increase. The 52-week range is $23.75 to $53.25.
  • Biogen Idec Inc. (NASDAQ: BIIB) up nearly $3.00, a 5% increase to $61.94. Carl Icahn on CNBC said today he is going to stay after the company.  The 52-week range is $43.43 to $84.75.
  • Cephalon Inc.  (NASDAQ: CEPH) up a modest 1% to $65.35. Last Thursday, they received FDA approval for Treanda, a treatment for chronic lymphocytic leukemia. The 52-week high is $84.83.
  • Cytokinetics, Incorporated (NASDAQ: CYTK) up over 2% to $3.49. Today the company announced positive results from Phase IIa trials of cardiac myosin activator drug CK-1827452 for patients with stable heart failure.
  • Onyx Pharmaceuticals (NASDAQ: ONXX) up $1.94 to $29.36, over 7% up. The 52-week range is $23.73 to $61.18
  • Regeneron Pharmaceuticals (NASDAQ: REGN) up $2.21 to $19.86, a 12% increase on the day. The 52-week range is $13.55 to $28.74
  • Theravance Inc. (NASDAQ: THRX) up $1.13 to $10.53, a 12% jump. The 52-week range is $9.37 to $36.98.

One biotech stock that isn’t enjoying the upswing is Cambrex Corp. (NYSE: CBM). The company hit a new low, down over 13% to $6.95 on news that UCB Groups Parkinson’s treatment, Neupro, is being recalled. Neupro uses their ingredient and the recall should impact earnings. First Analyis Sec downgraded the stock today.

Rachel Lopez
March 24, 2008

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.